PreprintCited by 36

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry pathway and reduction of cell surface entry pathways

Yamamoto, Mizuki, Tomita, Keiko, Hirayama, Youko, Inoue, Jun-ichiro, Kawaguchi, Yasushi, Gohda, Jin·2022

Abstract

The SARS-CoV-2 Omicron variant reportedly displays decreased usage of the cell surface entry pathway mediated by the host transmembrane protease, serine 2 (TMPRSS2) and increased usage of the endosomal entry pathway mediated by cathepsin B/L. These differences result in different cell tropisms and low fusogenicity from other SARS-CoV-2 variants. Recent studies have revealed that host metalloproteases are also involved in cell surface entry and fusogenic activity of SARS-CoV-2, independent of TMPRSS2. However, the involvement of metalloproteinase-mediated cell entry and fusogenicity in Omicron infections has not been investigated. Here, we report that Omicron infection is less sensitive to the metalloproteinase inhibitor marimastat, like the TMPRSS2 inhibitor nafamostat, and is more sensitive to the cathepsin B/L inhibitor E-64d than infections with wild-type SARS-CoV-2 and other variants. The findings indicate that Omicron preferentially utilizes the endosomal pathway rather than cell surface pathways for entry. Moreover, the Omicron variant also displays poor syncytia formation mediated by metalloproteinases, even when the S cleavage status mediated by fusion-like proteases is unchanged. Intriguingly, the pseudovirus assay showed that a single mutation, H655Y, of the Omicron spike (S) is responsible for the preferential entry pathway usage without affecting the S cleavage status. These findings suggest that the Omicron variant has altered entry properties and fusogenicity, probably through the H655Y mutation in its S protein, leading to modulations of tissue and cell tropism, and reduced pathogenicity. Author summary: Recent studies have suggested that the SARS-CoV-2 Omicron variant displays altered cell tropism and fusogenicity, in addition to immune escape. However, comprehensive analyses of the usage of viral entry pathways in Omicron variant have not been performed. Here, we used protease inhibitors to block each viral entry pathway mediated by the three host proteases (cathepsin B/L, TMPRSS2, and metalloproteinases) in various cell types. The results clearly indicated that Omicron exhibits enhanced cathepsin B/L-dependent endosome entry and reduced metalloproteinase-dependent and TMPRSS2-dependent cell surface entry. Furthermore, the H655Y mutation of Omicron S determines the relative usage of the three entry pathways without affecting S cleavage by the host furin-like proteases. Comparative data among SARS-CoV-2 variants, including Omicron, may clarify the biological and pathological phenotypes of Omicron but increase the understanding of disease progression in infections with other SARS-CoV-2 variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2022.03.21.485084

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Omicron variant displays preferential usage of endosomal pathway over cell surface entry pathways.
Fig 1 Omicron variant displays preferential usage of endosomal pathway over cell surface entry pathways.CC-BY · From the PDF
Fig 2 Omicron variant displays poor syncytium formation mediated by metalloproteinases.
Fig 2 Omicron variant displays poor syncytium formation mediated by metalloproteinases.CC-BY · From the PDF
Fig 3 H655Y mutation in Omicron S protein facilitates viral entry through the endosomal pathway.
Fig 3 H655Y mutation in Omicron S protein facilitates viral entry through the endosomal pathway.CC-BY · From the PDF
SFig 1. Effects of protease inhibitors on SARS-CoV-2 infection.
SFig 1. Effects of protease inhibitors on SARS-CoV-2 infection.CC-BY · From the PDF
SFig 2. Effects of protease inhibitors on infection with VSV pseudoviruses bearing S proteins derived from SARS-CoV-2 variants.
SFig 2. Effects of protease inhibitors on infection with VSV pseudoviruses bearing S proteins derived from SARS-CoV-2 variants.CC-BY · From the PDF
SFig 3. Effects of marimastat on syncytia formation of HEC50B cells induced by infection with WT, Omicron, and Delta virus.
SFig 3. Effects of marimastat on syncytia formation of HEC50B cells induced by infection with WT, Omicron, and Delta virus.CC-BY · From the PDF
Image 7
CC-BY · From the PDF
SFig 5. Prediction of additional hydrogen bond formation between tyrosine residue at position 655 (Y655) of Omicron S1 domain and threonine residue at position 696 (T696) in S2 domain.
SFig 5. Prediction of additional hydrogen bond formation between tyrosine residue at position 655 (Y655) of Omicron S1 domain and threonine residue at position 696 (T696) in S2 domain.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 36

  1. 10.1038/s41586-022-04441-6 · DOI
  2. 10.1038/s41586-022-04462-1 · DOI
  3. 10.1038/s41586-022-04442-5 · DOI
  4. 10.3390/ijms23041987 · DOI
  5. 10.1016/j.cell.2021.12.033 · DOI · Paper page
  6. 10.1056/NEJMc2119407 · DOI
  7. 10.1016/j.cell.2021.12.032 · DOI · Paper page
  8. 10.1038/s41586-021-04386-2 · DOI
  9. 10.1038/s41586-022-04479-6 · DOI
  10. 10.1038/s41586-022-04474-x · DOI · Paper page
  11. 10.21203/rs.3.rs-1191837/v1 · DOI · Paper page
  12. 10.1038/s41580-021-00418-x · DOI · Paper page
  13. 10.1126/science.abb2762 · DOI
  14. 10.1038/s41586-020-2180-5 · DOI · Paper page
  15. 10.1016/j.cell.2020.02.052 · DOI · Paper page
  16. 10.1038/s41392-021-00558-8 · DOI
  17. 10.1101/2021.12.14.472513 · DOI
  18. 10.1016/j.cell.2020.10.030 · DOI
  19. 10.1126/scitranslmed.abj7521 · DOI
  20. 10.1038/s41418-021-00782-3 · DOI
  21. 10.1016/j.ebiom.2020.103104 · DOI
  22. 10.1038/s41586-021-04266-9 · DOI
  23. 10.15252/embj.2021108944 · DOI
  24. 10.3390/v12060629 · DOI
  25. 10.1128/AAC.01043-16 · DOI
  26. 10.1093/cid/ciaa325 · DOI
  27. 10.1016/j.chom.2020.06.020 · DOI
  28. 10.1371/journal.ppat.1009373 · DOI
  29. 10.1101/2021.08.05.455290 · DOI
  30. 10.26508/lsa.202000786 · DOI · Paper page
  31. 10.1016/j.cell.2020.09.032 · DOI · Paper page
  32. 10.1038/s41586-020-2772-0 · DOI
  33. 10.1038/s41422-020-00430-4 · DOI
  34. 10.1101/2022.01.25.477784 · DOI
  35. 10.1073/pnas.2009799117 · DOI
  36. 10.4062/biomolther.2020.201 · DOI

Cited by

Sorted by citations

Metadata

Authors
Yamamoto, M., Tomita, K., Hirayama, Y., Inoue, J.-I., Kawaguchi, Y., & Gohda, J.
Publisher
openRxiv
Published
2022-03-21
Cited by
36
References
6
Type
Preprint

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review